GERON CORP Proceeds from Sale of Available-for-sale Securities, Equity
GERON CORP (GERN) reported Proceeds from Sale of Available-for-sale Securities, Equity of $1.00 thousand for the 12-month period ending 2011-12-31, per its 10-K filed 2014-03-17.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity · last filed 2014-03-17
- GERON CORP proceeds from sale of available-for-sale securities, equity for the quarter ending 2011-12-31 was $0.00.
- GERON CORP proceeds from sale of available-for-sale securities, equity for the quarter ending 2010-12-31 was $0.00.
- GERON CORP proceeds from sale of available-for-sale securities, equity for fiscal 2011 was $1.00K.
- GERON CORP proceeds from sale of available-for-sale securities, equity for fiscal 2010 was $0.00, a 100.00% decline from fiscal 2009.
- GERON CORP proceeds from sale of available-for-sale securities, equity for fiscal 2009 was $1.00K.
| Period end | Proceeds from Sale of Available-for-sale Securities, Equity 3 month | Proceeds from Sale of Available-for-sale Securities, Equity 9 month | Proceeds from Sale of Available-for-sale Securities, Equity 12 month |
|---|---|---|---|
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $1.00K 10-K · filed 2014-03-17 | |
| 2011-09-30 | $1.00K 10-Q · filed 2012-11-02 | ||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-07 | $0.00 10-K · filed 2012-03-07 | |
| 2010-09-30 | $0.00 10-Q · filed 2011-11-03 | ||
| 2009-12-31 | $1.00K 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |